AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of ARS 417.73 trillion. The enterprise value is 453.43 trillion.
| Market Cap | 417.73T |
| Enterprise Value | 453.43T |
Important Dates
The next estimated earnings date is Tuesday, February 10, 2026.
| Earnings Date | Feb 10, 2026 |
| Ex-Dividend Date | Aug 8, 2025 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | +0.13% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 80.59% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 32.43 and the forward PE ratio is 18.60.
| PE Ratio | 32.43 |
| Forward PE | 18.60 |
| PS Ratio | 5.24 |
| PB Ratio | 6.63 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 24.08 |
| P/OCF Ratio | 20.13 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.04, with an EV/FCF ratio of 26.14.
| EV / Earnings | 35.20 |
| EV / Sales | 5.37 |
| EV / EBITDA | 15.04 |
| EV / EBIT | 19.63 |
| EV / FCF | 26.14 |
Financial Position
The company has a current ratio of 0.88, with a Debt / Equity ratio of 0.71.
| Current Ratio | 0.88 |
| Quick Ratio | 0.69 |
| Debt / Equity | 0.71 |
| Debt / EBITDA | 1.57 |
| Debt / FCF | 2.58 |
| Interest Coverage | 12.24 |
Financial Efficiency
Return on equity (ROE) is 21.67% and return on invested capital (ROIC) is 13.16%.
| Return on Equity (ROE) | 21.67% |
| Return on Assets (ROA) | 9.06% |
| Return on Invested Capital (ROIC) | 13.16% |
| Return on Capital Employed (ROCE) | 19.78% |
| Revenue Per Employee | 844.78M |
| Profits Per Employee | 136.60M |
| Employee Count | 94,300 |
| Asset Turnover | 0.53 |
| Inventory Turnover | 1.59 |
Taxes
In the past 12 months, AstraZeneca has paid 2.79 trillion in taxes.
| Income Tax | 2.79T |
| Effective Tax Rate | 17.79% |
Stock Price Statistics
The stock price has increased by +79.97% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +79.97% |
| 50-Day Moving Average | 67,052.50 |
| 200-Day Moving Average | 52,985.38 |
| Relative Strength Index (RSI) | 55.88 |
| Average Volume (20 Days) | 228 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, AstraZeneca had revenue of ARS 79.66 trillion and earned 12.88 trillion in profits. Earnings per share was 8,248.60.
| Revenue | 79.66T |
| Gross Profit | 66.33T |
| Operating Income | 21.80T |
| Pretax Income | 15.68T |
| Net Income | 12.88T |
| EBITDA | 27.98T |
| EBIT | 21.80T |
| Earnings Per Share (EPS) | 8,248.60 |
Balance Sheet
The company has 11.21 trillion in cash and 44.76 trillion in debt, giving a net cash position of -33,548.47 billion.
| Cash & Cash Equivalents | 11.21T |
| Total Debt | 44.76T |
| Net Cash | -33,548.47B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 63.00T |
| Book Value Per Share | 40,547.71 |
| Working Capital | -5,638.24B |
Cash Flow
In the last 12 months, operating cash flow was 20.75 trillion and capital expenditures -3,401.58 billion, giving a free cash flow of 17.35 trillion.
| Operating Cash Flow | 20.75T |
| Capital Expenditures | -3,401.58B |
| Free Cash Flow | 17.35T |
| FCF Per Share | n/a |
Margins
Gross margin is 83.26%, with operating and profit margins of 27.37% and 16.17%.
| Gross Margin | 83.26% |
| Operating Margin | 27.37% |
| Pretax Margin | 19.68% |
| Profit Margin | 16.17% |
| EBITDA Margin | 35.12% |
| EBIT Margin | 27.37% |
| FCF Margin | 21.78% |
Dividends & Yields
This stock pays an annual dividend of 795.69, which amounts to a dividend yield of 1.11%.
| Dividend Per Share | 795.69 |
| Dividend Yield | 1.11% |
| Dividend Growth (YoY) | 39.02% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 52.89% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.19% |
| Earnings Yield | 3.08% |
| FCF Yield | 4.15% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 2.98 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.98 |
| Piotroski F-Score | 7 |